These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31628935)

  • 21. The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease.
    Maskery M; Goulding EM; Gengler S; Melchiorsen JU; Rosenkilde MM; Hölscher C
    Am J Alzheimers Dis Other Demen; 2020; 35():1533317520953041. PubMed ID: 32959677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
    Ji C; Xue GF; Li G; Li D; Hölscher C
    Rev Neurosci; 2016 Jan; 27(1):61-70. PubMed ID: 26351802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
    Perry T; Lahiri DK; Sambamurti K; Chen D; Mattson MP; Egan JM; Greig NH
    J Neurosci Res; 2003 Jun; 72(5):603-12. PubMed ID: 12749025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of GLP-1/GIP receptor agonists in Alzheimer's disease.
    Yu CJ; Ma D; Song LL; Zhai ZN; Tao Y; Zhang Y; Cai LY; Hou YH; Chen HY; Wang L
    Adv Clin Exp Med; 2020 Jun; 29(6):661-668. PubMed ID: 32614526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model.
    Li T; Tu L; Gu R; Yang XL; Liu XJ; Zhang GP; Wang Q; Ren YP; Wang BJ; Tian JY
    Life Sci; 2020 Sep; 256():117824. PubMed ID: 32445758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
    McClean PL; Parthsarathy V; Faivre E; Hölscher C
    J Neurosci; 2011 Apr; 31(17):6587-94. PubMed ID: 21525299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.
    Wang ZJ; Han YF; Zhao F; Yang GZ; Yuan L; Cai HY; Yang JT; Holscher C; Qi JS; Wu MN
    Horm Behav; 2020 Feb; 118():104640. PubMed ID: 31765661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
    Cao Y; Hölscher C; Hu MM; Wang T; Zhao F; Bai Y; Zhang J; Wu MN; Qi JS
    Eur J Pharmacol; 2018 May; 827():215-226. PubMed ID: 29551659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.
    Li T; Jiao JJ; Hölscher C; Wu MN; Zhang J; Tong JQ; Dong XF; Qu XS; Cao Y; Cai HY; Su Q; Qi JS
    Hippocampus; 2018 May; 28(5):358-372. PubMed ID: 29473979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca
    Li T; Jiao JJ; Su Q; Hölscher C; Zhang J; Yan XD; Zhao HM; Cai HY; Qi JS
    Neuropharmacology; 2020 Jun; 170():108042. PubMed ID: 32147454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C
    Recent Pat CNS Drug Discov; 2010 Jun; 5(2):109-17. PubMed ID: 20337586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [No Abstract]   [Full Text] [Related]  

  • 36. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
    Hölscher C
    Alzheimers Dement; 2014 Feb; 10(1 Suppl):S47-54. PubMed ID: 24529525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice.
    Yang S; Zhao X; Zhang Y; Tang Q; Li Y; Du Y; Yu P
    Peptides; 2024 Sep; 179():171271. PubMed ID: 39002758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ; Hölscher C
    Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.